DDX39B and sIL7R Biomarker Screening for Early MS Risk Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting multiple sclerosis (MS) are often ineffective at early identification, as they typically rely on clinical symptoms that appear after significant neuronal damage has occurred.
Innovation Solution
A method involving the analysis of biological samples to detect lower levels of RNA Helicase DDX39B and elevated levels of soluble Interleukin-7 Receptor (sIL7R), which are associated with an increased risk of developing MS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If clinical symptom-based detection methods are used for multiple sclerosis, then the diagnostic approach is simple and widely applicable, but the detection timing is delayed until after significant neuronal damage has occurred
Solution Approach 1:
The patent applies preliminary action by detecting MS risk markers (DDX39B expression levels and sIL7R levels) before clinical symptoms manifest. This allows identification of individuals at high risk for developing MS, enabling early intervention before irreversible neuronal damage occurs. The method screens for biological markers that predict disease development, acting in advance of traditional symptom-based diagnosis.
2Loss of time
If genetic and phenotypic screening for DDX39B and sIL7R markers is implemented, then early identification of at-risk individuals is enabled, but the device complexity and testing procedures increase
Solution Approach 1:
The patent applies segmentation by dividing the MS risk assessment into distinct measurable components: DDX39B expression level detection and sIL7R level detection. Each marker can be assessed separately through specific biological assays, allowing the complex risk evaluation to be broken into manageable testing steps that can be performed independently and then integrated for comprehensive risk stratification.
Data Source
AI summary
The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.